News

Under the terms of the agreement, Pharmacyclics has acquired Celera technology and intellectual property relating to drugs that target histone deacetylase (HDAC) enzymes, selective HDAC enzymes, angiogenesis molecules

The company said that patient screening and enrollment for the first of two human trials designed to determine the safety pharmacokinetics of QR-333 will begin immediately. A phase

Results of the primary endpoint for this trial, eight-hour wake after sleep onset (WASO), which is an objective measure of sleep maintenance using polysomnography in a sleep laboratory

Approximately 50% of the Israel Ministry of Industry and Trade funding is designated for R&D expenditures within Israel and 50% is designated for international expenditures. A portion of

MedPharm aims to reduce onset of action to less than 30 minutes through nasal delivery of a reformulated benzodiazepine compared with the one to two hours taken by

The application is based upon the safety and efficacy results of two large randomized pivotal phase III special protocol assessment trials, North American Trial MM-009 and International Trial

The additional shares brings Wyeth’s stake in the company to 80%. Financial terms of the deal were not disclosed. According to Wyeth, growth of Wyeth KK (WKK) is

According to Schering-Plough which markets the drug in the US, Avelox monotherapy at 400mg once daily is as effective as the high-dose combination of 500mg of levofloxacin taken

Under the terms of the agreement, the university (UCSF) is granted a limited license to utilize Sunesis’ fragment-based drug discovery technology Tethering, for academic purposes. UCSF intends to